Compare ELVN & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVN | DAVE |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.6B |
| IPO Year | 2020 | N/A |
| Metric | ELVN | DAVE |
|---|---|---|
| Price | $15.61 | $219.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $41.00 | ★ $282.17 |
| AVG Volume (30 Days) | ★ 796.1K | 342.8K |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 224.46 |
| EPS | N/A | ★ 10.12 |
| Revenue | N/A | ★ $491,301,000.00 |
| Revenue This Year | N/A | $56.88 |
| Revenue Next Year | N/A | $18.07 |
| P/E Ratio | ★ N/A | $21.88 |
| Revenue Growth | N/A | ★ 53.84 |
| 52 Week Low | $13.30 | $65.46 |
| 52 Week High | $25.37 | $286.45 |
| Indicator | ELVN | DAVE |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 54.16 |
| Support Level | $15.88 | $188.00 |
| Resistance Level | $18.05 | $232.27 |
| Average True Range (ATR) | 1.13 | 10.75 |
| MACD | -0.16 | 2.54 |
| Stochastic Oscillator | 9.68 | 70.93 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.